CD160 and B-cell chronic lymphocytic leukemia: Nevertheless, the role of CD160 in CLL pathogenesis and the impairment of antitumor immune cells in the CLL microenvironment makes it a promising target in CLL, and relevant therapeutic approaches may be developed.